Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 28, Issue 6, 2010, Pages 936-941

  Blasberg, Justin D ^a   Pass, Harvey I ^a   Goparaju, Chandra M ^a   Flores, Raja M ^a   Lee, Suzie ^a   Donington, Jessica S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATININE; OSTEOPONTIN;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER SURGERY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; THORACOTOMY; VALIDATION PROCESS; BLOOD; CANCER STAGING; CASE CONTROL STUDY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77949890243     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.5711     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Nesbitt JC, Putnam JB Jr, Walsh GL, et al: Survival in early-stage non-small-cell lung cancer. Annals Thor Surg 60:466-472, 1995
3. Hoffman PC, Mauer AM, Vokes EE: Lung cancer. Lancet 35:479-485, 2000 (Pubitemid 30085163)
4. Rami-Porta R, Ball D, Crowley J, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2:593-602, 2007 (Pubitemid 47171780)
5. Chu DZ, Erickson CA, Russell MP, et al: Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence. Arch Surg 126:314-316, 1991
6. Sung HJ, Cho JY: Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41:615-625, 2008
7. Senger DR, Wirth DF, Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16:885-893, 1979 (Pubitemid 9161338)
8. O'Regan A: The role of osteopontin in lung disease. Cytokine Growth Factor Rev 14:479-488, 2003
9. Ashkar S, Weber GF, Panoutsakopoulou V, et al: Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 287:860-864, 2000 (Pubitemid 30084330)
10. Liaw L, Birk DE, Ballas CB, et al: Altered wound healing in mice lacking a functional osteopontin gene. J Clin Invest 101:1468-1478, 1998 (suppl 1) (Pubitemid 28166845)
11. Das R, Philip S, Mahabeleshwar GH, et al: Osteopontin: Its role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 57:441-447, 2005 (Pubitemid 41073126)
12. Denhardt DT, Guo X: Osteopontin: A protein with diverse functions. Faseb J 7:1475-1482, 1993 (Pubitemid 24003267)
13. Behrend EI, Craig AM, Wilson SM, et al: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54:832-837, 1994 (Pubitemid 24068345)
14. Gardner HA, Berse B, Senger DR: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9:2321-2326, 1994 (Pubitemid 24228683)
15. Hu Z, Lin D, Yuan J, et al: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small-cell lung cancer. Clin Cancer Res 11:4646-4652, 2005 (Pubitemid 41557181)
16. Le QT, Chen E, Salim A, et al: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small-cell lung cancers. Clin Cancer Res 12:1507-1514, 2006
17. Mack PC, Redman MW, Chansky K, et al: Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26:4771-4776, 2008
18. Isa S, Kawaguchi T, Teramukai S, et al: Serum osteopontin levels are highly prognostic for survival in advanced non-small-cell lung cancer: Results from JMTO LC 0004. J Thorac Oncol 4:1104-1110, 2009
19. Pass HI, Lott D, Lonardo F, et al: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564-1573, 2005 (Pubitemid 41434635)
20. Mazumdar M, Glassman JR: Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19(113-132, 2000
21. Brown DJ, Milroy R, Preston T, et al: The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol 60:705-708, 2007 (Pubitemid 46975230)
22. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract 2:416-422, 2005 (Pubitemid 43115010)
23. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
24. Brown LF, Papadopoulos-Sergiou A, Berse B, et al: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610-623, 1994 (Pubitemid 24285968)
25. Shijubo N, Uede T, Kon S, et al: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160:1269-1273, 1999 (Pubitemid 29487470)
26. Donati V, Boldrini L, Dell'Omodarme M, et al: Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459-6465, 2005 (Pubitemid 41338982)
27. Zhang H, Ye QH, Ren N, et al: The prognostic significance of presurgery plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132:709-717, 2006 (Pubitemid 44337931)
28. Cui BK, Zhang CQ, Zhang Y, et al: Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma [in Chinese]. Ai Zheng 25:876-879, 2006
29. Kim JH, Skates SJ, Uede T, et al: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287:1671-1679, 2002 (Pubitemid 34289219)
30. Singhal H, Bautista DS, Tonkin KS, et al: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605-611, 1997 (Pubitemid 27211840)
31. Koopmann J, Fedarko NS, Jain A, et al: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13:487-491, 2004 (Pubitemid 38737477)
32. Le QT, Sutphin PD, Raychaudhuri S, et al: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67, 2003 (Pubitemid 36109716)
33. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57:373-380, 2007 (Pubitemid 47285428)
34. Cho HJ, Kim HS: Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 11:206-213, 2009
35. O'Regan AW, Chupp GL, Lowry JA, et al: Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 162:1024-1031, 1999 (Pubitemid 29035430)
36. O'Regan AW, Hayden JM, Berman JS: Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 68:495-502, 2000